Emergent BioSolutions will keep outgoing CFO Richard Lindahl involved in its 2026 annual report after vice president and treasurer Frank Vargo takes over the interim finance roles Jan. 1, 2027.
Vargo will hold the interim CFO and principal financial and accounting officer posts, while Lindahl will step down from both positions Dec. 31, 2026.
Lindahl is due to serve as a senior executive adviser from Jan. 1 through March 31, 2027, his scheduled retirement date. His advisory work will include assisting with Emergent’s Form 10-K for the fiscal year ending Dec. 31, 2026.
Starting Jan. 1, 2027, the interim assignment will pay Vargo an additional $3,850 per pay period alongside his $328,000 base salary. Lindahl said he was “committed to ensuring a smooth and successful transition.”
